引用次数
引用: 27,393
H-指数: 81
I10-指数 : 322
出版物: 749
Functional Activity of a Recombinant Anti-Ganglioside GD2-IL2 Fusion Protein
J. A. Hank , J. Surfus , S. D. Gillies , P. Jaeger
Journal of Immunotherapy 16 ( 3) 237
1994
A PHASE IB STUDY OF GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR AND INTERLEUKIN-2: CLINICAL AND IMMUNOLOGICAL EFFECTS
J. A. Hank , J. E. Surfus , J. H. Schiller , M. Khorsand
Journal of Immunotherapy 18 ( 2) 128
1995
Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy.
P. M. Sondel , B. R. Javorsky , J. A. Hank , M. J. Lindstrom
Clinical Cancer Research 4 ( 5) 1287 -1296
6
1998
Interaction of IL-15 with the shared IL-2 receptor beta and gamma c subunits. The IL-15/beta/gamma c receptor-ligand complex is less stable than the IL-2/beta/gamma c receptor-ligand complex.
P. M. Sondel , J. L. O. De Jong , J. G. Giri , M. B. Widmer
Journal of Immunology 156 ( 4) 1339 -1348
69
1996
Phlebotomy with Iron Therapy to Correct the Microcytic Polycythemia of Chronic Hypoxia
P. M. Sondel , D. J. Ganick , J. M. Levy , M. E. Tripp
Pediatrics 67 ( 5) 667 -670
13
1981
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
P. M. Sondel , P. M. Sondel , G. Weil-Hillman , G. Weil-Hillman
Cancer Research 49 ( 23) 6832 -6839
23
1989
Harnessing graft versus leukemia: implications for IL-2 treatment.
H. Kawai , O. H. Wesly , P. M. Sondel
Bone Marrow Transplantation 10 ( 1) 13 -15
3
1992
Improved renal allograft survival following donor-specific transfusions. I. Induction of antibodies that inhibit primary antidonor MLC response.
W. J. Burlingham , P. M. Sondel , H. W. Sollinger , E. M. F. Sparks
Transplantation 39 ( 1) 12 -17
21
1985
Evidence that gene products other than the known major histocompatibility complex class II determinants can stimulate a proliferative immune response
P. M. Sondel , R. DeMars , P. J. Reitnauer
Transplantation Proceedings 17 779 -780
1985
Epstein-Barr virus transformed lymphoblastoid cell lines (LCLs) can present soluble antigen to primed lymphocytes
P. M. Sondel , J. A. Hank , L. R. Brown , P. J. Reitnauer
Federation Proceedings 43 ( 6)
1984
The graft versus leukemia (GVL) effect following bone marrow transplantation (BMT): A review of laboratory and clinical data
P. M. Sondel , J. A. Sosman
Hematology Reviews and Communications 2 ( 1) 77 -91
6
1987
Interleukin-2 mediated activation of jak3 in the absence of a detectable 04 kda common 7 chain
J. J. O'Shea , T. S. Fenske , T. S. Fenske , P. M. Sondel
The FASEB Journal 10 ( 6)
1996
Potential role for the IL-2 receptor gamma chain in receptor complexes of other members of the cytokine receptor superfamily
T. P. Leary , J. Gan , N. L. Farner , W. L. Farrar
Journal of Cellular Biochemistry Suppl 1994(18 Part A) 18
1994
Phase II trial of hu14.18-IL2 (EMD 273063) for patients with metastatic melanoma
M. R. Albertini , J. A. Hank , H. Schalch , J. Kostlevy
Journal of Clinical Oncology 26 ( 15_suppl) 9039 -9039
3
2008
Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study
S. Shusterman , W. B. London , S. D. Gillies , J. A. Hank
Journal of Clinical Oncology 26 3002 -3002
14
2008
Cell Mediated Lysis of Lymphocytes Expressing Bacterial Antigens
J. A. Hank , P. M. Sondel
Advances in Experimental Medicine and Biology 162 189 -195
1983
Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain.
S. D. Voss , T. P. Leary , P. M. Sondel , R. J. Robb
Proceedings of the National Academy of Sciences of the United States of America 90 ( 6) 2428 -2432
69
1993
LYSIS OF HUMAN TUMOR CELL LINES BY CANINE COMPLEMENT PLUS MONOCLONAL ANTI-GANGLIOSIDE ANTIBODIES OR NATURAL CANINE XENOANTIBODIES
S. C. Helfand , R. L. Donner , J. A. Hank , P. M. Sondel
Journal of Immunotherapy 16 ( 3) 237
1994
COMBINED IMMUNOLOGIC THERAPY WITH INTERLEUKIN-2 AND ANTI-GD-2 MONOCLONAL ANTIBODY 14.G2a INDUCES IN VIVO IMMUNOLOGIC CONDITIONS ABLE TO MEDIATE ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN VITRO, IN PEDIATRIC NEUROBLASTOMA PATIENTS
J. A. Hank , J. Surfus , J. Gan , R. Hong
Journal of Immunotherapy 11 ( 2) 126
1992
FUNCTIONAL AND MOLECULAR ANALYSES OF THIOGUANINE-RESISTANT T-LYMPHOCYTES IN MELANOMA PATIENTS
M. R. Albertini , K. T. Tans , M. Falta , J. A. Nicklas
Journal of Immunotherapy 13 ( 1) 55
1993